ResearcherNorthwestern UniversityActive in the last 2 years
Rosa Bianca Schmuck
Matched on ORCID iD 0000-0003-2812-0656; OpenAlex author ID A5062511549. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 26
2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 7
- Extracellular Matrix Mechanobiology in Pancreatic Ductal Adenocarcinoma: Correlating In Vivo Patient Magnetic Resonance Elastography with Ex Vivo Tissue Mechan… Co-author DOI 10.64898/2026.06.07.730664↗
- Cancer Associated Fibroblasts Derived from Pancreatic Adenocarcinoma and Their Role in Cell Migration. Last author DOI 10.21873/anticanres.15227↗
- TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
- Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. Last author DOI 10.1016/j.hbpd.2018.09.004↗
- The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2018.09.004↗
- Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patien… Co-author DOI 10.21873/anticanres.11952↗
- Axon guidance factor SLIT2 inhibits neural invasion and metastasis in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-1012↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marcus Bahra · 6 shared papers, 2014–2021 · strength 0.49
- Paper Cancer Associated Fibroblasts Derived from Pancreatic Adenocarcinoma and Their Role in Cell Migration. DOI 10.21873/anticanres.15227↗
- Paper TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Gene… DOI 10.1158/1078-0432.ccr-19-3034↗
- Paper Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. DOI 10.1016/j.hbpd.2018.09.004↗
- Oihane Mitxelena‐Iribarren · 1 shared paper, 2026 · strength 0.30
- Amaia Cipitria · 1 shared paper, 2026 · strength 0.30
- Ingolf Sack · 1 shared paper, 2026 · strength 0.30
- Ellen von Hoerschelmann · 2 shared papers, 2018–2021 · strength 0.22
- Christopher Neumann · 2 shared papers, 2018–2021 · strength 0.22
- Marianne Sinn · 2 shared papers, 2017–2020 · strength 0.16
- Paper TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Gene… DOI 10.1158/1078-0432.ccr-19-3034↗
- Paper Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy… DOI 10.21873/anticanres.11952↗
- Uwe Pelzer · 2 shared papers, 2018–2020 · strength 0.16
- Fritz Klein · 2 shared papers, 2017–2018 · strength 0.14
- Andréas Andreou · 2 shared papers, 2017–2018 · strength 0.14
- Timm Denecke · 2 shared papers, 2017–2018 · strength 0.14
- Matthäus Felsenstein · 1 shared paper, 2021 · strength 0.13
- Frédérik Damm · 1 shared paper, 2020 · strength 0.09
- Jana Käthe Striefler · 1 shared paper, 2020 · strength 0.09
- Bruno Valentin Sinn · 1 shared paper, 2020 · strength 0.09
- Philipp Lohneis · 1 shared paper, 2020 · strength 0.09
- Frederick Klauschen · 1 shared paper, 2020 · strength 0.09
- Carsten Denkert · 1 shared paper, 2020 · strength 0.09
- Helmut Oettle · 1 shared paper, 2020 · strength 0.09
- Hanno B. Riess · 1 shared paper, 2020 · strength 0.09
- Benjamin Struecker · 1 shared paper, 2018 · strength 0.07
- Thomas Malinka · 1 shared paper, 2018 · strength 0.07
- Bertram J. Wiedenmann · 1 shared paper, 2014 · strength 0.04
- Christian Fischer · 1 shared paper, 2014 · strength 0.04
- Andreas Göhrig · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.